Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors.
CD62P
COVID-19
Plasma marker
Platelet function
SARS-CoV-2 infection
Soluble P-selectin
Journal
Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
12
04
2022
revised:
13
06
2022
accepted:
30
06
2022
pubmed:
11
7
2022
medline:
20
7
2022
entrez:
10
7
2022
Statut:
ppublish
Résumé
The coronavirus disease-2019 (COVID-19) is a systemic disease with severe implications on the vascular and coagulation system. A procoagulant platelet phenotype has been reported at least in the acute disease phase. Soluble P-selectin (sP-sel) in the plasma is a surrogate biomarker of platelet activation. Increased plasma levels of sP-sel have been reported in hospitalized COVID-19 patients associated with disease severity. Here, we evaluated in a longitudinal study the sP-sel plasma concentration in blood donors who previously suffered from moderate COVID-19. 154 COVID-19 convalescent and 111 non-infected control donors were recruited for plasma donation and for participation in the CORE research trial. First donation (T1) was performed 43-378 days after COVID-19 diagnosis. From most of the donors the second (T2) plasma donation including blood sampling was obtained after a time period of 21-74 days and the third (T3) donation after additional 22-78 days. Baseline characteristics including COVID-19 symptoms of the donors were recorded based on a questionnaire. Platelet function was measured at T1 by flow cytometry and light transmission aggregometry in a representative subgroup of 25 COVID-19 convalescent and 28 control donors. The sP-sel plasma concentration was determined in a total of 704 samples by using a commercial ELISA. In vitro platelet function was comparable in COVID-19 convalescent and control donors at T1. Plasma samples from COVID-19 convalescent donors revealed a significantly higher sP-sel level compared to controls at T1 (1.05 ± 0.42 ng/mL vs. 0.81 ± 0.30 ng/mL; p < 0.0001) and T2 (0.96 ± 0.39 ng/mL vs. 0.83 ± 0.38 ng/mL; p = 0.0098). At T3 the sP-sel plasma level was comparable in both study groups. Most of the COVID-19 convalescent donors showed a continuous decrease of sP-sel from T1 to T3. Increased sP-sel plasma concentration as a marker for platelet or endothelial activation could be demonstrated even weeks after moderate COVID-19, whereas, in vitro platelet function was comparable with non-infected controls. We conclude that COVID-19 and additional individual factors could lead to an increase of the sP-sel plasma level.
Sections du résumé
BACKGROUND
The coronavirus disease-2019 (COVID-19) is a systemic disease with severe implications on the vascular and coagulation system. A procoagulant platelet phenotype has been reported at least in the acute disease phase. Soluble P-selectin (sP-sel) in the plasma is a surrogate biomarker of platelet activation. Increased plasma levels of sP-sel have been reported in hospitalized COVID-19 patients associated with disease severity. Here, we evaluated in a longitudinal study the sP-sel plasma concentration in blood donors who previously suffered from moderate COVID-19.
METHODS
154 COVID-19 convalescent and 111 non-infected control donors were recruited for plasma donation and for participation in the CORE research trial. First donation (T1) was performed 43-378 days after COVID-19 diagnosis. From most of the donors the second (T2) plasma donation including blood sampling was obtained after a time period of 21-74 days and the third (T3) donation after additional 22-78 days. Baseline characteristics including COVID-19 symptoms of the donors were recorded based on a questionnaire. Platelet function was measured at T1 by flow cytometry and light transmission aggregometry in a representative subgroup of 25 COVID-19 convalescent and 28 control donors. The sP-sel plasma concentration was determined in a total of 704 samples by using a commercial ELISA.
RESULTS
In vitro platelet function was comparable in COVID-19 convalescent and control donors at T1. Plasma samples from COVID-19 convalescent donors revealed a significantly higher sP-sel level compared to controls at T1 (1.05 ± 0.42 ng/mL vs. 0.81 ± 0.30 ng/mL; p < 0.0001) and T2 (0.96 ± 0.39 ng/mL vs. 0.83 ± 0.38 ng/mL; p = 0.0098). At T3 the sP-sel plasma level was comparable in both study groups. Most of the COVID-19 convalescent donors showed a continuous decrease of sP-sel from T1 to T3.
CONCLUSION
Increased sP-sel plasma concentration as a marker for platelet or endothelial activation could be demonstrated even weeks after moderate COVID-19, whereas, in vitro platelet function was comparable with non-infected controls. We conclude that COVID-19 and additional individual factors could lead to an increase of the sP-sel plasma level.
Identifiants
pubmed: 35810548
pii: S0049-3848(22)00307-3
doi: 10.1016/j.thromres.2022.06.014
pmc: PMC9252887
pii:
doi:
Substances chimiques
Biomarkers
0
P-Selectin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
120-124Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Références
Cell Death Dis. 2021 Jan 5;12(1):50
pubmed: 33414384
Lancet Haematol. 2020 Aug;7(8):e575-e582
pubmed: 32619411
Blood. 2021 Feb 25;137(8):1061-1071
pubmed: 33512415
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
JACC Basic Transl Sci. 2021 Mar;6(3):202-218
pubmed: 33649738
Eur Respir J. 2021 Sep 9;58(3):
pubmed: 33958433
Blood. 2020 Sep 10;136(11):1317-1329
pubmed: 32573711
Sci Adv. 2021 Sep 10;7(37):eabh2434
pubmed: 34516880
Sci Rep. 2021 Jun 23;11(1):13153
pubmed: 34162913
PLoS Biol. 2021 Feb 17;19(2):e3001109
pubmed: 33596198
Circ Res. 2020 Sep 17;:
pubmed: 32938299
Front Cardiovasc Med. 2021 Dec 10;8:795624
pubmed: 34957266
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
J Thromb Haemost. 2021 Dec;19(12):3139-3153
pubmed: 34538015
Thromb Haemost. 2020 Jun;120(6):949-956
pubmed: 32349133
Blood. 2020 Sep 10;136(11):1330-1341
pubmed: 32678428
J Thromb Haemost. 2020 Sep;18(9):2103-2109
pubmed: 32558075
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Platelets. 2021 Nov 17;32(8):1092-1102
pubmed: 33999778
Front Cell Dev Biol. 2022 Jan 17;9:770463
pubmed: 35111751
Hamostaseologie. 2022 Oct;42(S 01):S14-S23
pubmed: 36288732
Adv Ther. 2021 Jul;38(7):3911-3923
pubmed: 34086266
Int J Mol Sci. 2021 Jul 26;22(15):
pubmed: 34360707